Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04863248
Title Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)
Acronym PRESERVE 4
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors G1 Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Ironwood Cancer & Research Centers Phoenix Arizona 85028 United States Details
Valkyrie Clinical Trials Los Angeles California 90067 United States Details
Desert Hematology Oncology Medical Group, Inc Rancho Mirage California 92270 United States Details
Innovative Clinical Research Institute - Oncology Whittier California 90602 United States Details
Mid-Florida Hematology Oncology Orange City Florida 32763 United States Details
Indiana University Health Goshen Cancer Center Goshen Indiana 46526 United States Details
St. Louis Cancer Care, LLP Bridgeton Missouri 63044 United States Details
Summit Medical Group Florham Park New Jersey 07932 United States Details
Regional Cancer Car Associates, LLC Little Silver New Jersey 07739 United States Details
Gettysburg Cancer Center Gettysburg Pennsylvania 17325 United States Details
University of Tennessee Medical Center Knoxville Tennessee 37920 United States Details
Millennium Oncology Houston Texas 77090 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field